Djordje Filipovic | Chief Executive Officer
AB2 Bio Ltd.

Dr. Djordje Filipovic.is currently serving as the CEO of AB2Bio, a Swiss Biotech Company focused on developing best in class innovative therapies for the treatment of Interleukin-18 (IL-18) driven systemic inflammatory disorders with high unmet medical needs. Djordje’s background includes more than 25 years in the Pharmaceutical Industry with extensive therapeutic expertise spanning Oncology (solid tumors, hematology), Immunology (derm, rheum, GI), Neurology, CV/Met, and Rare diseases. He brings deep knowledge in Oncology modalities, including precision oncology, radiopharmaceuticals, cell & gene therapy, and immunotherapy. His broad functional expertise encompasses General Management, Strategic Planning, Business Development, Commercial Strategy & Execution, Project & Portfolio Management, Late- & Early-stage Drug Development, Investor Relations, and Finance. Djordje joined AB2 Bio from Novartis, where held various positions of increasing responsibility holding functional leadership and general management positions in multiple divisions and departments at global (Basel and U.S.), regional and local (Bern, Germany and Iran) levels. Djordje was the Global Executive Leader for paradigm shifting Novartis brands like Glivec® and Xolair®, lead the Novartis Cell & Gene Therapy and Novartis Oncology Global Project & Portfolio Management organizations, served as Chairman of the Novartis Oncology Portfolio Management Board and in various General Management roles in Switzerland, Iran and the “Asia Middle-East Africa” Regional Executive Committee. An important priority for Djordje was the development of the “Emerging Markets Brands” concept, to enable access to innovation in countries with low-income levels in order to reach many more patients compared to traditional commercialization approaches. Prior to joining the Research Division of Sandoz, a predecessor Company of Novartis, in 1992, Djordje worked in the field of Protein Engineering at the University of Illinois and Battelle Labs with the Swiss National Science Foundation and the U.S. Department of Energy. A graduate from the Swiss Federal Institute of Technology (ETH) in Zürich, Djordje holds a Ph.D. in Biochemistry & Biophysics and a M.S. in Biochemistry. He lectures at the European Center of Pharmaceutical Medicine (ECPM) of the Basel University Medical School on Strategic Portfolio Management, Trends in Drug Development and Leadership. He is also a member of the ECPM Advisory Board and the Advisory Board of the Basel University School of Economics Center for International Economics and Business (CIEB). Djordje has been elected as lifelong member to the Swiss National Academy of Engineering (SATW) honouring his contributions to “Development & Commercialization of Innovation in Medicine and as an Entrepreneur”. He is a member of the SATW Scientific Council and SATW Industry Council.